Showing results (11-20 of 96) with videos related to
Sort By:
Pageof 10
Cancer Research|September 1, 2016
Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD PromoterRentian Wu, Qian Nie, Erin E Tapper, et al.British Journal of Clinical Pharmacology|January 25, 2021
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicitySeid Hamzic, Dominic Schärer, Steven M Offer, et al.Pharmacogenomics|November 22, 2005
Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogeneticsRichie Soong, Robert B DiasioSeminars in Oncology|February 24, 2005
Perspectives in the treatment of colorectal cancerHoward Ozer, Robert B DiasioDrugs|August 16, 2006
Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the artRobert B Diasio, Jeanne FouriePharmacogenomics|February 28, 2007
Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapyXue Zhang, Robert B DiasioClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2010
ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?Adam M Lee, Robert B DiasioClinical Colorectal Cancer|June 3, 2005
Edotecarin: a novel topoisomerase I inhibitorM Wasif Saif, Robert B DiasioCancer Chemotherapy and Pharmacology|June 10, 2016
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiencyMuhammad Wasif Saif, Robert B DiasioPharmacogenomics|August 8, 2002
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomicsLori K Mattison, Richie Soong, Robert B DiasioPageof 10